View : 498 Download: 0
The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study
- Title
- The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study
- Authors
- Kang S.H.; Lee M.; Kim M.Y.; Lee J.H.; Jun B.G.; Kim T.S.; Choi D.H.; Suk K.T.; Kim Y.D.; Cheon G.J.; Kim D.J.; Baik S.K.
- Ewha Authors
- 이민종
- SCOPUS Author ID
- 이민종
- Issue Date
- 2021
- Journal Title
- Hepatology International
- ISSN
- 1936-0533
- Citation
- Hepatology International vol. 15, no. 2, pp. 424 - 436
- Keywords
- Ascites; Esophageal varix; Hepatic venous pressure gradient; Liver cirrhosis; Low-dose non-selective β-blockers; Nonselective β-blockers; Portal hypertension; Severity; Survival; Treatment
- Publisher
- Springer
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background/Aim: We investigated the effect of non-selective β-blockers (NSBB) in real-world situations and whether low-dose NSBB is beneficial compared to maximally tolerated doses. Methods: We performed a retrospective study of 740 patients with cirrhosis requiring prophylactic treatment of esophageal varices: 473 primary prophylaxis (PP: NSBB = 349, non-NSBB = 124) and 267 secondary prophylaxis (SP: NSBB = 200, non-NSBB = 67). The NSBB group was divided into low-dose (≤ 80 mg/day) and high-dose (> 80 mg/day). Results: In the PP group, NSBB treatment reduced mortality and showed the most pronounced effect in patients with moderate/severe ascites (hazard ratio [HR], 0.46; p < 0.01), HVPG ≥ 16 mmHg (HR, 0.53; p = 0.04), or CTP class B/C (HR, 0.46; p < 0.01) but not in those with no/mild ascites, HVPG < 16 mmHg, or CTP class A. Low-dose NSBB group showed a significant reduction in mortality compared with non-NSBB (moderate/severe ascites: HR, 0.61; p = 0.02 and CTP class B/C: HR, 0.41; p < 0.01) and the effect size was stronger than the high-dose NSBB. NSBB was associated with a reduced risk of infection (HR, 0.36; p = 0.01). In the SP group, NSBB prolonged survival in patients with moderate/severe ascites (HR, 0.56; p = 0.02), HVPG ≥ 16 mmHg (HR, 0.42; p < 0.01), or CTP class B/C (HR, 0.52; p < 0.01). Low-dose NSBB was more beneficial with 56% risk reduction (p < 0.01) of mortality compared with 33% risk reduction in the high-dose NSBB (p = 0.05). Conclusion: NSBB therapy was associated with longer survival in PP and SP groups who had an advanced stage of cirrhosis. Moreover, low-dose NSBB exhibited a better benefit than a standard-titrated high-dose NSBB with better tolerability. © 2021, Asian Pacific Association for the Study of the Liver.
- DOI
- 10.1007/s12072-021-10160-3
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML